Literature DB >> 18310982

Sporadic adult-onset hypophosphatemic osteomalacia caused by excessive action of fibroblast growth factor 23.

Chisho Hoshino1, Noriyuki Satoh, Shinichi Sugawara, Chizuko Kuriyama, Akio Kikuchi, Masahiro Ohta.   

Abstract

A 50-year-old man without family history of metabolic bone disease was referred to our hospital with a 5-year history of progressively worsening spinal and bilateral diffuse leg pain and proximal muscle weakness. Two years before admission, he was diagnosed as ankylosing spondylitis by a rheumatologist and was maintained on low-dose prednisone therapy without benefit. He developed progressive spinal and thoracic deformities, resulting in a 10 cm loss in height in the preceding 2 years. On physical examination, marked thoracic kyphosis and pectus carinatum was noted. Plain radiograph revealed pseudofracture in the right femoral neck. Laboratory findings showed a normal level of serum calcium, elevated level of serum alkaline phosphatase and inappropriately increased urinary phosphate excretion despite extreme hypophosphatemia. He was diagnosed as adult-onset hypophosphatemic osteomalacia caused by renal phosphate wasting. Serum fibroblast growth factor 23 was the upper limit of normal despite extreme hypophosphatemia and no neoplastic lesion potentially inducing hypophosphatemic osteomalacia could be identified in a thorough search including imaging studies of his entire body. Oral administration of phosphate and activated vitamin D together with dipyridamole relieved the persistent pain and weakness, and he became fully ambulatory.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18310982     DOI: 10.2169/internalmedicine.47.0665

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Hypophosphatemic osteomalacia: a case simulating anklylosing spondylitis treated with anti-TNF therapy.

Authors:  F Sivas; F G Yurdakul; M Durak; G Hatipoğlu; E D Önal; H Bodur
Journal:  Osteoporos Int       Date:  2016-09-12       Impact factor: 4.507

Review 2.  FGF23 and its role in X-linked hypophosphatemia-related morbidity.

Authors:  Signe Sparre Beck-Nielsen; Zulf Mughal; Dieter Haffner; Ola Nilsson; Elena Levtchenko; Gema Ariceta; Carmen de Lucas Collantes; Dirk Schnabel; Ravi Jandhyala; Outi Mäkitie
Journal:  Orphanet J Rare Dis       Date:  2019-02-26       Impact factor: 4.123

Review 3.  Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases.

Authors:  Ariadne Bosman; Andrea Palermo; Julien Vanderhulst; Suzanne M Jan De Beur; Seiji Fukumoto; Salvatore Minisola; Weibo Xia; Jean-Jacques Body; M Carola Zillikens
Journal:  Calcif Tissue Int       Date:  2022-07-20       Impact factor: 4.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.